NOW. - AI-Based Drug Repurposing Could Offer New Lifesaving Medicine
Forbes - The promise of a virus-fighting biotech
San Diego Business Journal - AI may be used to find new cures in old drugs
Empowered Patient Podcast - Using AI to Identify Combinations of Drugs to Fight COVID-19 with Daniel Cohen, Pharnext
Reuters - BRIEF-Pharnext Announces Partnership To Evaluate Drugs For Potential Use Against COVID-19
Reuters - BRIEF-Pharnext identifies frequently prescribed drugs to be repurposed for fighting Covid-19
ZDNet - We need a Big Data effort to find a COVID-19 cure, says pioneering geneticist
CMT News - PXT3003 Improves Clinical Outcomes and Stabilizes Disease Progression in CMT1A Patients, Extension Study Shows
CMT News - Is a Treatment for CMT in the Works?
Forbes - Biotech Investors Are Flocking to Paris
Counsel & Heal - How AI is Finding New Cures in Old Drugs
Fortune Magazine - How A.I. Is Finding New Cures in Old Drugs
CMT News - Short-term PXT3003 Treatment Delays Disease Onset in Rat Model of CMT1A, Study Shows
The Sun - Rare ‘invisible’ and inherited disease leaves adults with strength of a child...
WCBS - Alzheimers, then Tchaikovsky...
WCBS - Reversing Peripheral Nerve Damage
WCBS - What’s Pleotherapy?
WCBS - Le President de la Republique Wants To Know...
WCBS - The Piano’s Loss Was Science’s Gain
The Straits Times - China seeks new markets for ancient medicines as it modernises TCM remedies
CMT News - International CMT&Me Observational Study to Explore the Impact of CMT Using an App
BioWorld - Pharnext shares rise on phase III readout in CMT1A disease
CMT News - PXT3003 Eases Disability, Found Safe in CMT1A Patients, Phase 3 Trial Shows
FierceBiotech - Pharnext muscle wasting phase 3 hits primary endpoint
LaBiotech.eu - Drug Combination for Rare Genetic Nerve Disorder Nails Phase III
BioWorld - Pharnext shares rise on phase III readout in Charcot-Marie-Tooth disease
RARE Daily - Pharnext Reports Positive Topline Results from Late-Stage Charcot-Marie-Tooth Trial
EndPoint News - Pharnext rare disease drug scores in late-stage study, teeing up applications at the FDA and EMA
BioCentury - Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data
BioTuesday - Pharnext platform taps genomic data, AI for new combination medicines
Page 1 of 3